CARMAT signs agreement with Edwards Lifesciences for total artificial heart

“This partnership with Edwards Lifesciences will enable us to secure a major milestone of our total artificial heart with a view to providing a solution for patients suffering from end-stage heart failure”

CARMAT (Paris:ALCAR), the designer and developer of the world's most advanced artificial heart, today announced that it has signed an agreement with Edwards Lifesciences, the global leader in the science of heart valves and hemodynamic monitoring. According to this agreement, CARMAT will be using the Carpentier-Edwards' biological heart valves in its artificial heart.

Carpentier-Edwards biological heart valves were developed by CARMAT co-founder and CSO Professor Alain Carpentier and will be, for the very first time, used in an artificial heart.

"This partnership with Edwards Lifesciences will enable us to secure a major milestone of our total artificial heart with a view to providing a solution for patients suffering from end-stage heart failure," emphasized CARMAT CEO Marcello Conviti.

The Carpentier-Edwards biological heart valves with proven design, technology, efficacy, and reliability (recognized in the medical world) are essential components of CARMAT's artificial heart.

This agreement matches CARMAT's philosophy and very high standards of its artificial heart.